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Circulating antibody to Tamm-Horsfall protein (THP) was measured using a radioimmu-
noassay in forty-five patients on maintenance hemodialysis and compared to levels ofantibody
titers measured in sera from ten healthy controls. The etiology of the end-stage kidney disease in
the patient population was polycystic kidney disease in thirteen, glomerulonephritis in fourteen,
diabetic nephropathy in nine, interstitial nephritis and chronic pyelonephritis in three each,
multiple myeloma in two, and urinary tract obstruction in one. Four patients had significantly
elevated titers ofantibody to THP but shared no other unifying characteristics. The results also
indicate that none of the groups studied had mean antibody titers significantly different from
controls. Furthermore, no general trend was apparent between levels ofantibody to THP and
number of months on dialysis.
Observations made during the study revealed that heparinized samples of blood had lower
titers ofantibody to THP than did non-heparinized samples from the same patient. This finding
was repeated when otheranti-coagulants, i.e., ethylenediaminetetraacetate (EDTA) and sodium
citrate, were used. Titers returned toward normal when CaC12 was added back to samples anti-
coagulated with EDTA and sodium citrate. This suggests that clotting factors, probably
fibrinogen, interfered with the measurement ofantibody titers. Therefore, only serum should be
used in further investigations of THP antibody using this assay.
INTRODUCTION
Since its discovery and characterization by Tamm and Horsfall in 1950 [1], the
importance of the 80,000 molecular weight urinary glycoprotein, known as Tamm-
Horsfall protein(THP), remains unknown. Only the cells liningtheascending loop of
Henle and distal convoluted tubule synthesize this protein, which is secreted into the
tubular lumen [2,3]. No physiological role for the protein is known although THP is
known to inhibit hemagglutination caused by influenza, mumps, and Newcastle
disease virus [1], but has no effect on bacteria [4]. Approximately 50 mg of THP is
excreted per day in human urine. Inthe presence oflowpH or high salt concentration
in the urine, the protein aggregates and forms casts [4-6].
Recent work suggests that THP may play a role in some pathological processes
affecting the kidney including calculi formation [7] and other precipitates which may
cause microscopic tubular obstruction [8]. Also THP may be involved in the
pathogenesis of some interstitial diseases of the kidney. Intrarenal deposits of THP
have been described in medullary cystic disease [9], chronic pyelonephritis, and
hydronephrosis [9,10] as well as in end-stage reflux nephropathy. Furthermore, rats
immunized with homologous THP develop an immune complex tubulo-interstitial
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nephritis characterized by mononuclear cell infiltrates and immune globulin deposi-
tion at the tubular location where THP is synthesized [11]. Nevertheless, the role of
THP in the pathogenesis of these diseases has not been clearly defined.
Previous work by others in humans and experimental animals has shown that
severe urinary tract obstruction and vesicoureteral reflux may cause reflux of urine
into the venous and lymphatic circulation as well as into the renal parenchyma
[12-14]. Consequently, the potential development of a circulating antibody response
to substances found only in the urine, such as THP, might permit early non-invasive
diagnosis of these conditions [12]. In fact, abnormal circulating antibodies to THP
have been detected in experimental animals with vesicoureteral reflux [12], in
schoolage girls with acute symptomatic upper urinary tract infection [15], and, by
earlier work from this laboratory, in adults with acute urinary tract obstruction and
infection [16]. Although the role ofcirculatingantibodies to THP in the pathogenesis
ofthese acute diseases remains unclear, severe vesicoureteral reflux and urinarytract
obstruction can lead to silent renal destruction and end-stage renal disease in some
patients [16-20]. Except for acute pyelonephritis, urinary tract obstruction, and
vesicoureteral reflux, antibody to THP has not been determined previously in
patients with other types of renal involvement, and in particular in patients with end-
stage renal disease. Therefore, such a study seemed warranted in order to try to better
understand the role, if any, of THP antibody in the pathogenesis of these diseases.
The present report describes THP antibody in patients with end-stage renal disease
on maintenance hemodialysis, with diagnoses ofurinary tract obstruction, interstitial
nephritis, and chronic pyelonephritis, and compares them with patients with other
causes of end-stage renal disease including polycystic kidney disease, glomerulone-
phritis, and diabetic nephropathy, as well as healthy control subjects. Specifically,
our purpose was to determine whether elevated titers ofantibody to THP were also
present in patients with chronic renal disease caused by different pathologic pro-
cesses, as well as whetherantibody titers correlated with specific types ofrenal injury.
MATERIALS AND METHODS
Patient Selection
A total of forty-five chronic hemodialysis patients at Yale-New Haven Hospital
and the West Haven Veterans Administration Hospital participated in this study
after giving informed consent. The diagnosis of renal failure in each patient was
based on clinical, radiological, or histological evidence. In addition, information
about urinary tract infection (UTI), current and past medications, and length oftime
on dialysis was obtained from the patient's hospital record.
Patients were placed into groups based upon the etiology of their renal failure.
These groups included: (1) thirteen patients with polycystic kidney disease (PCKD) in
whom the diagnosis was made by intravenous pyelography (IVP) or laparotomy; (2)
nine patients with diabetic nephropathy (DN), in whom the diagnosis was made on
clinical evidence of diabetes mellitus and sequellae including cataracts and retinopa-
thy in eight, and in one a history of diabetes and a biopsy which showed interstitial
nephritis; (3) fourteen patients with glomerulonephritis (GN), eleven of whom had
biopsies, which showed membranoproliferative GN in three, membranous GN in
two, chronic progressive hypocomplementemic GN in one, and chronic GN (CGN) in
five, and in the remaining three patients without biopsy, the diagnosis of CGN was
based on a history of acute GN which progressed to renal failure in one, a history of
beta hemolytic streptococcal infection followed by hematuria, albuminuria, and
progressive renal failure in another, and a history of skin infections leading to
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progressive renal failure in the third; (4) six patients with the diagnosis of chronic
pyelonephritis (CPN) or interstitial nephritis (IN), based on a history of phenacetin
abuse in one, neomycin-induced deafness and renal failure in one, biopsy in two, and
by renal scan and pyelography in the other two; (5) one patient with urinary tract
obstruction (UTO) diagnosed by IVP; and (6) two patients with multiple myeloma
(secretory type) who developed renal failure with progression of their disease.
Blood Collection
All patients received heparin during dialysis with an initial bolus of 5000 U
followed by three hourly 1000 U doses until dialysis ended after four hours. Heparin
antagonists were not given to any of the patients.
Blood was obtained from each patient for determination of anti-THP antibody
titers. In order to evaluate the effect of dialysis on titers ofanti-THP antibody, 5 ml
samples ofblood were obtained from participants pre- and post-dialysis. The samples
from Yale-New Haven Hospital were collected in plain vacutainers and allowed to
clot at room temperature for one hour before serum was removed. The samples from
the West Haven Veterans Administration Hospital were collected in heparinized
vacutainers (approximately 120U Hep) and the plasma removed immediately.
Sodium azide was added to each specimen for bacteriostasis.
Urine
Clean catch urine specimens were obtained for culture from all patients who were
not anuric. Quantitative urine cultures were performed by the standard pour plate
technique. Bacteria recovered were identified by the scheme of Schaub and Foley
[21].
THP Antibody
Serum antibody titers to THP were determined by a radioimmunoassay initially
developed in this laboratory and described in detail in previous publications [16,22].
The assay depends on binding specific antibody to a solid phase antigen (THP
adsorbed to a microtiter plate). The subsequent identification ofbound antibody was
achieved by adding 125I labeled protein A which binds to the Fc region of IgG [23].
Serial dilutions of rabbit sera containing known amounts of specific antibody to
human THP were assayed simultaneously with the patient samples to obtain a
standard curve for conversion of counts per minute to ng antibody/ml.
Heparin Effect
Preliminary results indicated that the heparinized samples consistently contained
lower anti-THP titers than unheparinized samples. Further studies were done to
evaluate the effect of heparin on the assay.
Heparinized and non-heparinized samples from medical student volunteers were
obtained to evaluate the effect of heparin on freshly collected samples. The non-
heparinized samples were allowed to clot for one hour and the serum was then
removed. The heparinized samples were immediately centrifuged and plasma re-
moved. All samples received sodium azide as a preservative.
To evaluate the effect heparin might have directly on antigen-antibody binding in
the assay, heparin, in amounts approximately equal to 5, 10, 50, and 100 times the
calculated concentration ofheparin in patients' serumimmediately following dialysis,
was added to serum from a rabbit immunized to human THP. The amount of
heparin added was calculated by approximating the heparin T1/2 in serum at 60
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minutes [24] for the amounts used. Samples containing rabbit serum and heparin
were then evaluated for anti-THP activity and compared to serum from the same
rabbit to which no heparin was added.
In order to determine whether heparin exerted a specific effect, or if the inhibition
observed was a result of some other plasma component, i.e., fibrinogen, blood
samples anticoagulated with ethylenediaminetetraacetate (EDTA) and sodium citrate
were compared to samples which were heparinized and to samples which were not
anticoagulated. Four samples of blood were taken from each often volunteers; one
sample without anticoagulant, one with heparin, one with EDTA, and one with
sodium citrate. As a further study to evaluate the effect of fibrinogen on the assay,
samples collected with EDTA and citrate were defibrinated by adding back CaCl2.
This was done by incubating samples and CaCl2 (final concentration in samples
0.025M) for one hour at 370C and then at 40C for twelve hours [25]. The resulting
clot was removed and the samples assayed.
Statistical Methods
Significantly elevated titers were defined as antibody titers greater than the mean
level plus two standard deviations observed in healthy control subjects [16]. Inde-
pendent groups were compared using T statistics for independent data, heparin vs.
serum comparisons were made using the paired T test.
RESULTS
THP Antibody
The titer of Tamm-Horsfall antibody in the serum ofpatients with end-stage renal
disease and in healthy volunteers is shown in Fig. 1 and is expressed in cpm as well as
ng/ml of antibody. The mean anti-THP antibody titer in ten healthy subjects was
1050 ng/ml and the mean plus two standard deviations was 1920 ng/ml. Any titer
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above this value was considered significantly elevated. The mean anti-THP antibody
titer in serafromthe thirteen patients with PCKD was 721 * 341 ng/ml and none was
significantly elevated. The mean value of anti-THP antibody in sera from fourteen
patients with GN was 1348 1503 ng/ml, which included two patients with signifi-
cantly elevated titers of 5132 and 4437 ng/ml. The mean titer in sera from nine
patients with DN was 1328 ± 1161 ng/ml and included one patient with a titer of4329
ng/ml. The mean antibody titer in sera from the three patients with CPN was
1485 ± 338 ng/ml and none was significantly elevated. The mean titer in sera fromn the
three patients with IN was 1591 ± 506 ng/ml and included a significantly elevated
titer of 2045 ng/ml in one patient. The mean titer in sera from the two patients with
multiple myeloma (MM) was 340 ±37 ng/ml and was the lowest for any single
diagnostic group. The serum from the one patient with UTO gave a titer of 1090
ng/ml.
The mean values for anti-THP antibody for each of the groups were not
significantly different from the mean value for healthy subjects. The highest mean of
1591 ng/ml was seen in patients with IN, followed by 1485 ng/ml in patients with
CPN, 1348 ng/ml in GN, 1328 ng/ml in DN, 1090 ng/ml in UTO, 721 ng/ml in
PCKD, and 340 ng/ml in MM. Urine cultures were obtained from twenty-three
patients, twelve of whom had significant bacteriuria. Urine cultures could not be
obtained from twenty-two patients who wereanuric. Sera from thefour patients with
E. coli bacteriuria had a meantiter of 1640 ± 1280 ng/ml ofanti-THP antibody. Sera
from the eight other patients with infected urine had a mean anti-THP antibodytiter
of 876 i 257 ng/ml. Sera from the eleven patients with sterile urine had a mean titer
of850 i 376 ng/ml and the twenty-two patients who were anuric had a mean titer of
1180 775 ng/ml. Individual results appear in Fig. 2. None ofthe groups ofpatients
was significantly different from the healthy subjects. Of the four patients with
significantly elevated titers, one had an E. coli UTI and the other three were anuric.
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The chemical data and antibody levels to Tamm-Horsfall protein in these forty-five
patients with end-stage renal disease are shown in Table 1.
The relationship ofeach patient's serum anti-THP antibody titer to the number of
months on dialysis at the time ofthis study is shown in Fig. 3. Figures 4-7 show the
same function for each diagnostic group, PCKD (Fig. 4); DN (Fig. 5); GN (Fig. 6);
CPN (Fig. 7) and IN (Fig. 7). Significantly elevated titers were observed in 1/11
patients dialyzed for twenty months or less and in 3/14 patients dialyzed between
twenty and forty months. None of the other patients dialyzed for forty months or
longer had elevated titers.
Effect of Heparin
Pre-dialysis samples of blood obtained frompatients at Yale-New Haven Hospital
were considered free of heparin effect since blood was obtained 48 hours after
previous dialysis and heparinization. Pre-dialysis samples (non-heparinized at Yale-
New Haven Hospital, heparinized at the West Haven Veterans Administration
Hospital) and post-dialysis samples (heparinized during dialysis at both hospitals)
were compared by hospital. There is a suggestion of significant differences between
means of pre- (1237 ng/ml) and post- (1081 ng/ml) samples at Yale-New Haven
Hospital (p = .03) while there is no significant difference between pre- (637 ng/ml)
and post- (666 ng/ml) samples at the West Haven Veterans Administration Hospital
(p = 0.64).
Figure 8 presents results of serum and plasma anti-THP titers in ten volunteers
expressed in cpm. Each volunteer gave two samples of blood, one heparinized and
one not heparinized. The mean antibody titer for non-heparinized samples was 7530
cpm ±4040 cpm, and the mean antibody titer in heparinized samples was 5590
cpm i 2780 cpm (Table 2). These means are significantly different (p = 0.003).
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The effect of adding heparin to hyperimmune rabbit serum is shown in Fig. 9. The
final concentration of added heparin was 5, 10, 50, and 100 times the calculated
concentration of heparin in patients' serum at the end of dialysis. THP antibody
levels remained the same in hyperimmune rabbit serum regardless of the concentra-
tion of added heparin, which suggests that the heparin molecule itselfdoes not affect
the method for measuring antibody.
Effect of Other Anticoagulants
The effect of other anticoagulants on the level of Tamm-Horsfall antibody in
serum was studied in ten healthy subjects, each of whom contributed four freshly
drawn samples of blood. Either heparin, sodium citrate, EDTA, or no anticoagulant
(control) was added to one of the samples from each subject, after which the level of
antibody was determined. Calcium chloride was then added to each sample and the
antibody level was measured again. The results are presented in Table 3 and show a
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significant difference in measured antibody titers between control serum (non-
anticoagulated) and sodium citrated blood (p = 0.003), between control serum and
blood anticoagulated with EDTA (p = 0.004), as well as between control serum and
heparinized blood (p = 0.01). All three anticoagulants significantly reduced the titer
of measured antibody. However, the addition of calcium chloride to blood anticoag-
ulated with sodium citrate resulted in a return of measured antibody titer toward
normal. Although the antibody titer in citrated blood to which calcium chloride had
been added was lower than that observed in control serum with (p = 0.01) or without
(p = 0.02) calcium chloride, it was significantly higher than that observed in citrated
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FIG. 8. Measurement of antibody to Tamm-Horsfall
Protein (THP) in cpm in a 1:8 dilution of serum in non-
HEPARIN heparinized and heparinized samples fromvolunteers. Bar
10 graphs represent one standard deviation.
TABLE 2
Levels of Antibody to Tamm-Horsfall Protein (THP) in Heparinized and Non-Heparinized Serum
Samples Collected from Healthy Subjects
THP Antibody in cpm*
Subject Non-Heparinized Heparinized
KB 5,140 3,270 -36
GC 4,340 4,290 -I
BF 2,800 2,490 -11
ML 11,090 6,430 -42
BS 5,320 4,730 -11
JW 5,180 4,930 -5
DB 9,970 7,400 -25
JB 16,310 12,280 -25
JK 6,510 3,980 -39
BS 8,660 6,030 -30
mean = 7,530 mean = 5,590
s.d. = 4,040 s.d. = 2,780
*cpm = counts per minute
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TABLE 3
The Effect of Three Anticoagulants With and Without Calcium Chloride on Tamm-Horsfall Protein
Antibody Levels in Healthy Subjects
Control Citrate EDTA Heparin
Subject Control Citrate EDTA Heparin +CaCl2 +CaC12 +CaCl2 +CaCl2
AM 3570* 2500 2280 2230 2380 2100 2340 1860
SD 2630 2230 2610 2400 2950 2135 2890 2120
TM 2710 2334 2400 2250 3150 2820 3070 2590
BC 3620 2590 2820 3090 3200 3190 3170 2820
RD 1830 1430 1510 1780 2130 1970 1990 1560
JS 2950 2300 2330 2660 3020 2560 2680 2410
SD 5120 3670 4300 3770 3770 3370 4130 4070
JW 3180 2060 2380 3090 3290 3360 4050 3070
SS 6290 4070 5310 4180 5200 4530 6480 5310
DB 7020 4040 4560 4230 5390 5410 4270 4120
MEAN = 3890 2720 3050 2970 3450 3140 3510 2990
S.D. = 1690 894 1230 860 1080 1110 1300 1180
*Counts per minute of I125
blood without calcium chloride (p = 0.05). Similar results were observed when
calcium chloride was added to blood anticoagulated with EDTA. In fact, there was
no significant difference in antibody titer between control serum with (p = 0.78) or
without (p = 0.27) calcium chloride and EDTA anticoagulated blood to which
calcium chloride had been added, whereas there was a significantly higher antibody
titer in EDTA plus calcium chloride treated blood as compared with blood anticoag-
ulated with EDTA alone (p = 0.04). In contrast, the addition ofcalcium chloride to
blood anticoagulated with heparin did not change the measured antibody titer
(p = 0.87). Specifically, antibody titers remained significantly lower in heparinized
blood to which calcium chloride was added as compared with control blood with
(p = 0.01) or without (p = 0.01) calcium chloride (Table 3).
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DISCUSSION
Previous attempts to identify antibody to kidney tissue in patients with pyelone-
phritis and chronic nephritis using complement fixation [26], latex agglutination [27],
and hemagglutination [28] have been unsuccessful. However, those assays were less
sensitive than the present one and could not identify circulating antibody in normal
controls. Using the present assay, Marier et al. [16] demonstrated small amounts of
antibody to THP in normal subjects and significantly elevated titers in patients with
acute urinary tract obstruction and infection. Hanson et al. [15] also observed
elevated titers of antibody to THP in 9/10 school-age girls with acute symptomatic
upper urinary tract infection using an enzyme linked immuno-absorbent assay.
The objective, in the present study, was to determine, using our new assay, whether
elevated titers ofantibody to THP were present in patients with various forms of end-
stage kidney disease. The results of the present study indicate that four of the forty-
five patients with chronic renal disease had significantly elevated titers of antibody to
THP, but they did not share any other unifying characteristic. Two patients with
glomerulonephritis dialyzed for three and twenty-six months, respectively, had
elevated titers, one of whom also had an
E cli urinary tract infection, though the
other was anuric. One patient with diabetic nephropathy dialyzed for thirty-one
months, had elevated titers and was anuric, and another anuric patient with elevated
titers and also dialyzed for thirty-one months, had kidney failure based on long-
standing interstitial nephritis. The present work indicates that none of the groups
studied had mean antibody titers significantly different from controls. Furthermore,
in all groups of patients studied, no general trend was apparent between levels of
antibody to THP and number of months on dialysis.
The present data do not exclude the possibility of elevated antibody titers at some
point in the progression of various types of kidney disease, but this study indicates
that titers of antibody to THP are not useful in diagnosing the cause or presence of
end-stage kidney disease. The patients reported in the present study have end-stage
renal disease and have been on dialysis for periods of one month to ten years. The
failure to detect elevated antibody titers in many of these patients might have been
expected since these patients were not likely to have active or progressive renal
disease at the time of study, and elevated antibody titers may be dependent on active
kidney disease. If this concept is true, then our observations would suggest that
further study to identify patients with elevated titers of antibody should involve
patients with active kidney disease. Such studies should include sequential determina-
tions to better define the time course of this antibody response.
During the course of these studies we observed a significant difference in antibody
titers between pre- and post-dialysis samples of blood obtained from patients at the
Yale-New Haven Hospital but not in samples obtained from patients at the West
Haven Veterans Administration Hospital. The pre-dialysis samples (serum) from
patients at Yale-New Haven Hospital were not anti-coagulated, while the samples
(plasma) from patients at the West Haven Veterans Administration Hospital were
anti-coagulated with heparin. Post-dialysis samples (plasma) at both hospitals were
collected identically and both were heparinized. These results suggest two important
findings: first, heparin interferes in some way with the quantitative measurement of
circulating antibody to THP, which explains the difference noted between pre
(serum) and post (plasma) dialysis samples obtained from patients at Yale-New
Haven Hospital; and second, dialysis has no effect on the quantity of circulating
antibody since pre- and post-dialysis samples (plasma) obtained from patients at the
West Haven Veterans Administration Hospital were the same. Further studies were
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performed to attempt to clarify the effect of heparin on the assay. Specifically,
heparin was added directly to hyperimmune serum obtained fromrabbits immunized
with human THP and no changes in antibody titers were noted. These results
suggested that the heparin molecule, which exists as a heterogenous assortment of
polymeric chains [29], did notdirectly interfere with the quantification ofantibody to
THP when that antibody was in serum obtained fromclotted blood. That is, heparin
did not appear to interfere directly with antigen-antibody binding but instead seemed
to act through or because of some substance present in plasma and not present in
serum, such as fibrinogen or heparin activated anti-thrombin III. Additional
experiments with other anti-coagulants, i.e., EDTA and sodium citrate, further
showed that the inhibition on lowered levels of measured antibody to THP observed
in heparinized-samples (plasma) also occurred when other anti-coagulants were used
to collect the blood and the assay was performed with the plasma obtained from these
samples. Antibody levels in samples of blood collected with these two chelators of
calcium returned near to control values whenfibrinogen was removed by the addition
of CaCl2 to the samples, but did not return toward normal when CaCl2 was added to
heparinized samples. These results suggested that anti-coagulants interfere indirectly
with the quantification of circulating antibody to THP and that clotting factors are
probably the source of this interference. Since calcium chelators halt the clotting
cascade by preventing conversion of prothrombin to thrombin (a calcium-dependent
step), which also prevents conversion of fibrinogen to fibrin, and heparin also stops
the clotting cascade by inhibiting certain activated factors: XIa [30], IXa [31], Xa
[32], and thrombin [33], and since the defect could be corrected by the addition of
CaCl2 to EDTA and citrated but not heparinized samples, the protein most likely to
interfere with this assay appears to be fibrinogen. Fibrinogen is the most plentiful of
the coagulation proteins and is preserved when all the above anti-coagulants are
used. These results indicate that anti-coagulated blood should be avoided in future
use of this assay to determine THP antibody levels, in order to prevent obtaining
spuriously low levels of THP antibody.
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